RESUMEN
Objectives While DNA profiling has become the principal technique for individualization of biological evidences, ABO blood grouping is still a useful test method in the initial stages of crime investigation. Objectives of the study were blood group determination using slide agglutination method, blood group determination from saliva using absorption inhibition method, and comparison of slide agglutination method with that of absorption inhibition method from saliva sample. Materials and Methods A total of 60 subjects were taken randomly with their age ranging from 20 to 60 years. Sixty subjects were divided in to two groups, study group and control group. 5 to 10 mL of unstimulated saliva was collected from 60 patients and Wieners agglutination test was performed to detect the secretor status of blood using absorption inhibition method and compared with that of slide agglutination method Results Out of 60 subjects, 52 subjects showed secretors of antigen in saliva with percentage value of 86.66% and eight subjects were nonsecretors (13.33%). Slightly higher percentage of secretor status was seen in males 84.6 and 88.2% in females. Conclusion Evaluation of secretor status of blood group antigen from saliva using absorption inhibition method can be useful method in identification of medicolegal cases.
RESUMEN
BACKGROUND: Patients with chronic kidney disease (CKD) face risks of not only end-stage kidney disease (ESKD), cardiovascular disease (CVD) and death, but also decline in kidney function, quality of life (QOL) and mental and physical well-being. This study describes the multidimensional trajectories of CKD using clinical events, kidney function and patient-reported outcome measures (PROMs). We hypothesized that more advanced CKD stages would associate with more rapid decline in each outcome. METHODS: Among 3939 participants enrolled in the Chronic Renal Insufficiency Cohort (CRIC) Study, we evaluated multidimensional disease trajectories by G- and A-stages of enrollment estimated glomerular filtration rate (eGFR) and albuminuria, respectively. These trajectories included clinical events (ESKD, CVD, heart failure and death), eGFR decline and PROMs [kidney disease QOL (KDQOL) burden, effects and symptoms questionnaires, as well as the 12-item short form mental and physical component summaries]. We also evaluated a group-based multitrajectory model to group participants on the basis of longitudinal PROMs and compared group assignments by enrollment G- and A-stage. RESULTS: The mean participant age was 58 years, 45% were women, mean baseline eGFR was 44 mL/min/1.73 m2 and median urine albumin:creatinine ratio was 52 mg/g. The incidence of all clinical events was greater and eGFR decline was faster with more advanced G- and A-stages. While baseline KDQOL and physical component measures were lower with more advanced G- and A-stage of CKD, changes in PROMs were inconsistently related to the baseline CKD stage. Groups formed on PROM trajectories were fairly distinct from existing CKD staging (observed agreement 60.6%) and were associated with the risk of ESKD, CVD, heart failure and death. CONCLUSIONS: More advanced baseline CKD stage was associated with a higher risk of clinical events and faster eGFR decline, and was only weakly related to changes in patient-reported metrics over time.